Is olaparib/olaparib a chemotherapy drug or a targeted drug?

Olaparib/Olaparib (Olaparib) is a targeted drug that belongs to the PARP inhibitor class. It is mainly used to treat certain types of cancer, especially ovarian cancer, breast cancer and other tumors related to BRCA gene mutations. PARP (poly(A-ribose polymerase)) is an important enzyme involved in the DNA repair process. When cells are damaged by DNA, PARP is activated and helps repair the damage. However, for those cells carrying BRCA1 or BRCA2 mutations, their self-repair ability is already impaired. At this time, the use of PARP inhibitors such as olaparib can further weaken the repair ability of cancer cells, leading to their death.

The mechanism of olaparib is to inhibit the activity ofPARP, making cancer cells unable to effectively repair DNA damage. This selective action makes olaparib effective in treating certain types of cancer, especially those who have developed resistance to traditional chemotherapy drugs. Unlike conventional chemotherapy drugs, which often work by directly killing fast-growing cells, Lynparza achieves its therapeutic effect by targeting specific biological pathways in cancer cells.

In clinical applications, olaparib is often used in patients whose disease has progressed despite having received other treatments, especially in the treatment of ovarian and breast cancer. Studies have shown that olaparib can significantly extend the progression-free survival of these patients and improve survival rate to a certain extent. Due to its targeting properties, olaparib has relatively few side effects. Common side effects include nausea, fatigue, anemia, etc., which are usually milder than those of traditional chemotherapy.

In addition, with in-depth research on tumor biomarkers, olaparib has also shown potential application value in other tumor types, such as pancreatic cancer and prostate cancer. These studies provide new ideas for future personalized treatments, which may benefit more patients.